---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-21-002894"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2021-09-02T23:59:59+00:00"
generated_at: "2026-06-29T06:07:02.589071+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Chemomab appoints Dale Pfost as CEO; co-founder Adi Mor becomes CSO

## Summary
- Dr. Dale Pfost appointed CEO, subject to shareholder approval expected Q4 2021.
- Dr. Adi Mor steps down as CEO, continues as Chief Scientific Officer and board member.
- Pfost brings 35 yrs experience; served as CEO of six biotech firms, including public companies.
- Pfost expected to join board and become Chairman in 2022 (subject to shareholder approval).
- Company has two Phase 2 studies underway; third expected to start in coming months.

## SEC filing metadata
- accession: 0001178913-21-002894
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2021-09-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891321002894/0001178913-21-002894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891321002894/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-21-002894
- JSON: https://secwatch.observer/filing/0001178913-21-002894.json
- Plain text: https://secwatch.observer/filing/0001178913-21-002894.txt

## Key facts
- Executive change
  Dale Pfost was appointed as Chief Executive Officer at Chemomab Therapeutics Ltd..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On September 2, 2021, Chemomab Therapeutics Ltd. (the “Company”) announced the appointment of Dr. Dale Pfost as Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534248/000117891321002894/0001178913-21-002894-index.htm
- Executive change
  Adi Mor changed role as Chief Scientific Officer at Chemomab Therapeutics Ltd..
  - Action: stepped down as CEO and continued as Chief Scientific Officer
  - Role: Chief Scientific Officer
  source text: Dr. Pfost will replace Dr. Adi Mor, who will step down from her role as Chief Executive Officer, effective as of the appointment of Dr. Pfost, and who will continue to be employed by the Company as Chief Scientific Officer where she will oversee scientific strategy and R&D operations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534248/000117891321002894/0001178913-21-002894-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.